戻る
Redhill Biopharma Ltd (RDHL)価格
RDHL 株価推移チャート
RDHL 収入
Redhill Biopharma Ltd
$1.36
3.81%
$0.05
終値： Jan 16, 16:00:00 GMT-5
$1.35
-0.02%
$0
アフターマーケット：Jan 16, 20:00:00 GMT-5
主要データ
前終値
$1.31
始値
$1.33
当日レンジ
$1.26 - $1.39
52週レンジ
$0.905 - $6.8
取引高
86.7K
平均取引高
1.3M
1株当たり利益(TTM)
-0.00
配当利回り
--
時価総額
$4.5M
RDHLとは何ですか？
RedHill Biopharma Ltd. engages in the development and commercialization of drugs for gastrointestinal (GI), infectious diseases, and oncology. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204, for pulmonary nontuberculous mycobacteria (NTM) disease; opaganib (ABC294640), host-directed, SPHK2 inhibitor targeting multiple indications, RHB-107 (upamostat), an oral, host-directed serine protease inhibitor with potential for pandemic preparedness, is in late-stage development for treatment of non-hospitalized symptomatic COVID-19, and is targeting multiple other cancer and inflammatory gastrointestinal diseases; RHB-104 for Crohn's disease; and RHB-102 for chemotherapy and radiotherapy induced nausea and vomiting.